VIRX - Viracta Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cardiff-by-the-Sea,
United States
Type: Equity
VIRX price evolution
VIRX
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.28 | |||
| Inventory | ||||
| Total current assets | $21.8 | $31.07 | $40.95 | $54.96 |
| Long term investments | ||||
| Property, plant & equipment | $0.11 | $0.21 | $0.34 | $0.46 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $21.96 | $31.32 | $41.33 | $56.69 |
| Current liabilities | ||||
| Accounts payable | $1.82 | $1.29 | $2.41 | $2.44 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $28.57 | $28.65 | $30.25 | $38.37 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $28.57 | $28.65 | $30.25 | $38.37 |
| Shareholders' equity | ||||
| Retained earnings | -$295.46 | -$284.9 | -$275.07 | -$265.93 |
| Other shareholder equity | $0.01 | -$0.01 | -$0.01 | $0.01 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.28 | |||
| Inventory | ||||
| Total current assets | $54.96 | $93.75 | $105.27 | $22.14 |
| Long term investments | ||||
| Property, plant & equipment | $0.46 | $0.41 | $0.88 | $0.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $56.69 | $95.99 | $108.55 | $23.25 |
| Current liabilities | ||||
| Accounts payable | $2.44 | $2.54 | $2.9 | $0.48 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $38.37 | $10.01 | $9.08 | $3.31 |
| Long term debt | $24.88 | $4.82 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $38.37 | $34.89 | $14.18 | $3.31 |
| Shareholders' equity | ||||
| Retained earnings | -$265.93 | -$214.87 | -$165.68 | -$704.41 |
| Other shareholder equity | $0.01 | -$0.18 | ||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $10.19 | $9.59 | $13.88 | $13.56 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.37 | -$0.24 | -$0.27 | -$0.2 |
| Net income | ||||
| Net income | -$10.55 | -$9.83 | -$9.14 | -$13.77 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.12 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $50.69 | $50.59 | $25.8 | $22.42 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.36 | $0.59 | -$0.45 | -$0.3 |
| Net income | ||||
| Net income | -$51.06 | -$49.2 | -$114.76 | -$21.61 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $34.05 | $25.89 | $14.19 | $15 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$8.48 | -$6.55 | -$6.6 | $0.44 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.81 | $1.66 | -$0.25 | -$24.46 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $15 | -$53.87 | $12.89 | $16.41 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.44 | $22.54 | $62.42 | $7.18 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$24.46 | -$66.79 | $56.47 | $2.15 |
News
Fundamentals
| Market cap | $794.88K |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 39.74M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$43.29M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.02 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.09 |
|---|---|
| ROA | -114.44% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.76 |
| Quick ratio | N/A |